|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0016011,
umls-concept:C0021701,
umls-concept:C0034656,
umls-concept:C0035173,
umls-concept:C0155626,
umls-concept:C0205195,
umls-concept:C0332206,
umls-concept:C0597357,
umls-concept:C0950902,
umls-concept:C1274040,
umls-concept:C1416485
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-4-3
|
|
pubmed:abstractText |
Platelet activation and aggregation may be key components of thrombolytic failure to restore and maintain perfusion in acute myocardial infarction. We performed a placebo-controlled, dose-ranging trial of Integrilin, a potent inhibitor of platelet aggregation, with heparin, aspirin, and accelerated alteplase.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0009-7322
|
|
pubmed:author |
pubmed-author:AndersonH VHV,
pubmed-author:CaliffR MRM,
pubmed-author:CohenM DMD,
pubmed-author:EllisS GSG,
pubmed-author:GaciochGG,
pubmed-author:KatzE SES,
pubmed-author:KereiakesDD,
pubmed-author:KleimanN SNS,
pubmed-author:KrucoffM WMW,
pubmed-author:MillerMM,
pubmed-author:NavettaF IFI,
pubmed-author:OhmanE MEM,
pubmed-author:SigmonK NKN,
pubmed-author:SpriggeJJ,
pubmed-author:TalleyJ DJD,
pubmed-author:TopolE JEJ,
pubmed-author:WorleyS JSJ,
pubmed-author:YakubovSS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
18
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
846-54
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9054741-Adult,
pubmed-meshheading:9054741-Aged,
pubmed-meshheading:9054741-Dose-Response Relationship, Drug,
pubmed-meshheading:9054741-Double-Blind Method,
pubmed-meshheading:9054741-Drug Therapy, Combination,
pubmed-meshheading:9054741-Electrocardiography,
pubmed-meshheading:9054741-Female,
pubmed-meshheading:9054741-Fibrinolytic Agents,
pubmed-meshheading:9054741-Heparin,
pubmed-meshheading:9054741-Humans,
pubmed-meshheading:9054741-Infusions, Intravenous,
pubmed-meshheading:9054741-Injections, Intravenous,
pubmed-meshheading:9054741-Male,
pubmed-meshheading:9054741-Middle Aged,
pubmed-meshheading:9054741-Monitoring, Physiologic,
pubmed-meshheading:9054741-Myocardial Infarction,
pubmed-meshheading:9054741-Peptides,
pubmed-meshheading:9054741-Placebos,
pubmed-meshheading:9054741-Platelet Aggregation,
pubmed-meshheading:9054741-Platelet Aggregation Inhibitors,
pubmed-meshheading:9054741-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:9054741-Tissue Plasminogen Activator
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
|
|
pubmed:affiliation |
Duke University Medical Center, Durham, NC 27710, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
